BioPorto: CEO Peter Mørch Eriksen will present the company’s strategic plan on Thursday February 22nd
BioPorto yesterday announced that CEO Peter Mørch Eriksen will present the company’s strategic plan on two events on Thursday February 22nd.
To participate in the digital event at HC Andersen Capital at 14:00 please sign in here: HCA Capital
To participate in the physical event at BioPorto’s Copenhagen office, Tuborg Havnevej 15, 2900 Hellerup, Denmark at 15:30, please sign up here: investor@bioporto.com
Disclaimer: HC Andersen Capital receives payment from Bioporto for a DigitalIR/Corporate Visibility agreement./ Henrik Ekman 13:38 20.02.2024
Login required
This content is only available for logged in users
BioPorto
BioPorto is a Danish in-vitro diagnostics company with headquarters in Copenhagen, Denmark. The company was founded in 2000. BioPorto has one marketed product, the NGAL test, for early diagnosis of acute kidney injury (AKI), which is commercially available in Europe, Canada, Asia, and Israel. It has received breakthrough designation from the FDA for AKI in the pediatric indication, for which it is currently conducting data analysis following the completion of enrollment of patients for its Phase 3 study which will lead to an expected application to FDA. Future plans include further FDA submission for adult indication as well as other markets.
Read more on company page